LIST OF CONTENTS

SEPTEMBER

Editorial	i	
Editorial Addresses	iii	
Steroid Nomenclature	vii	
Patricia L. Glikman, Andrea Manni, Mary Bartholomew and Laurence Demers	1	Polyamine involvement in basal and estradiol-stimulated insulin-like growth factor I secretion and action in breast cancer cells in culture
Neal B. West, Chawnshang Chang, Shutsung Liao and Robert M. Brenner	11	Localization and regulation of estrogen, progestin and androgen receptors in the seminal vesicle of the rhesus monkey
A. Tanaka, K. Matsumoto, Y. Nishizawa, J. Lu, H. Yamanishi, M. Maeyama, N. Nonomura, N. Uchida and B. Sato	23	Growth stimulation by androgens, glucocorticoids or fibroblast growth factors and the blocking of the stimulated growth by antibody against basic fibroblast growth factor in protein-free culture of Shionogi carcinoma 115 cells
T. Miyake, H. Komura, A. Tokuhira, T. Yamamoto, A. Miyake, O. Tanizawa, N. Terada, R. Yamamoto, S. Yoshida, M. Tsuji and H. Mori	31	Impaired development of mammary glands in scorbutic rats unable to synthesize ascorbic acid
S. Marivoet, M. Hertogen G. Verhoeven and W. Heyns	39	Antibodies against synthetic peptides recognize the human and rat androgen receptor
Sachiko Sugano, Naohiko Morishima and Shigeo Horie	47	Cytochrome $P\text{-}450_{scc}$-catalyzed production of progesterone from 22*R*-hydroxycholest-4-en-3-one by way of 20,22-dihydroxycholest-4-en-3-one
Miguel A. Fuentes, Thomas G. Muldoon and Virendra B. Mahesh	57	Role of 17β-hydroxysteroid dehydrogenase in the modulation of nuclear estradiol receptor binding by progesterone in the rat anterior pituitary gland and the uterus
Jorge A. Pineda, Gary L. Murdock, Robert J. Watson and James C. Warren	65	Stereospecificity of hydrogen transfer between progesterone and cofactor by human placental estradiol-17β dehydrogenase
Charles L. Mendenhall, Charles J. Grossman, Gary A. Roselle, Zsolt Hertelendy, Saad J. Ghosn, Kathy Lamping and Kim Martin	71	Anabolic steroid effects on immune function: differences between analogues
Jean N. DaSilva and Johan E. van Lier	77	*In vivo* evaluation of 7α-[11-(4-[^{125}I]iodophenoxy)undecyl]-17β-estradiol: a potential vector for therapy of adrenal and estrogen receptor-positive cancers
Alan L. Lin, James J. Schultz, Robert M. Brenner and Sydney A. Shain	85	Sexual dimorphism characterizes baboon myocardial androgen receptors but not myocardial estrogen and progesterone receptors
R. W. Kelly and A. Bukman	97	Antiprogestagenic inhibition of uterine prostaglandin inactivation: a permissive mechanism for uterine stimulation
Yoshihiro Endo and Eiichi Fujihira	103	Characteristics of glucocorticoid-binding by inflammatory tissue of rats
J. P. Wiebe, K. D. Buckingham, R. L. Zobell and F. Hertelendy	113	Metabolism of progesterone by avian granulosa cells in culture
Robert C. Tuckey	121	Side-chain cleavage of cholesterol sulfate by ovarian mitochondria

Frank Z. Stanczyk, Robert K. Matteri, Francine R. Kaufman, Elisabet Gentzschein and Rogerio A. Lobo	129	Androstenedione is an important precursor of dihydrotestosterone in the genital skin of women and is metabolized via 5α-androstanedione
H. Mochizuki, K. Suhara and M. Katagiri	133	Adrenal $P\text{-}450_{scc}$ catalyzes deoxycorticosterone 6β-hydroxylase reaction
Danielle Goudreault and Robert Massé	137	Studies on anabolic steroids—4. Identification of new urinary metabolites of methenolone acetate (Primobolan®) in human by gas chromatography/mass spectrometry
Adrian J. Bradley	155	Failure of glucocorticoid feedback during breeding in the male red-tailed phascogale *Phascogale calura* (Marsupialia: Dasyuridae)
Book Reviews	165	
Forthcoming Papers	I	

OCTOBER

General Review **L. P. C. Schot and A. H. W. M. Schuurs**	167	Sex steroids and osteoporosis: effects of deficiencies and substitutive treatments
V. R. Martins and M. M. Brentani	183	The effects of *ras* gene expression on glucocorticoid receptors in mouse fibroblasts
C. Ruedl, V. Cappelletti, D. Coradini, G. Granata and G. Di Fronzo	195	Influence of culture conditions on the estrogenic cell growth stimulation of human breast cancer cells
Aleksander W. Roszak, Yvonne A. Lefebvre, Gillian M. Howell and Penelope W. Codding	201	Structural requirements for the binding of dexamethasone to nuclear envelopes and plasma membranes
Jean S. Campbell and Harry J. Karavolas	215	Purification of the NADPH:5α-dihydroprogesterone 3α-hydroxysteroid oxidoreductase from female rat pituitary cytosol
Ahmed Berrada, Marc G. Denis, Philippe Blanchardie, Corinne Chadeneau and Patrick Lustenberger	223	Glucocorticoid effects and receptors in two rat colon carcinoma cell lines differing by their tumorigenicity
Masakazu Takahashi, Van Luu-The and Fernand Labrie	231	Inhibitory effect of synthetic progestins, 4-MA and cyanoketone on human placental 3β-hydroxysteroid dehydrogenase/5→4-ene-isomerase activity
M. A. Ghaffari and Y. J. Abul-Hajj	237	Reaction of thiol nucleophiles with 1,2-epoxy- and 4,5-epoxy-estrene-3-one-17β-ols
Carl M. Mendel, Martin B. Miller, Pentti K. Siiteri and James T. Murai	245	Rates of dissociation of steroid and thyroid hormones from human serum albumin
Carl M. Mendel	251	Rates of dissociation of sex steroid hormones from human sex hormone-binding globulin: a reassessment
Abdel-Rahim Ibrahim and Yusuf J. Abul-Hajj	257	Aromatase inhibition by flavonoids
M. Harnik, Y. Kashman, M. Cojocaru, H. Bauer, M. Laux, S. Lewicka and P. Vecsei	261	Synthesis of 4,19-disubstituted derivatives of DOC. Radioreceptor assay of some corticosteroid derivatives in human mononuclear leukocytes
Gianni Messeri, Paola Tozzi, Massimo Quercioli, Luigi Cataliotti and G. Cardona	269	Alkaline phosphatases and steroid receptors in human breast cancer
Arto K. Orpana, Mauri M. Orava, Reijo K. Vihko, Matti Härkönen and C. J. Peter Eriksson	273	Role of ethanol metabolism in the inhibition of testosterone biosynthesis in rats *in vivo*: importance of gonadotropin stimulation

Yvan Touitou, Andre Auzeby and Andre Bogdan — 279 — Cortisol and cortisone production in rat and mouse adrenal incubations

Quang D. Bui, Judith Weisz and Steven A. Wrighton — 285 — Hepatic catecholestrogen synthases: differential effect of sex, inducers of cytochromes *P*-450 and of antibody to the glucocorticoid inducible cytochrome *P*-450 on NADPH-dependent estrogen-2-hydroxylase and on organic hydroperoxide-dependent estrogen-2/4-hydroxylase activity of rat hepatic microsomes

Elio Napolitano, Rita Fiaschi and Robert N. Hanson — 295 — Estrogen receptor binding characteristics of 1,11β-ethanoestradiol: effect of a 1,11β-bridge on steroidal estrogen

Short Communication

M. J. Reed, M. S. Ross, L. C. Lai, M. W. Ghilchik and V. H. T. James — 301 — *In vivo* conversion of norethisterone to ethynyloestradiol in perimenopausal women

Forthcoming Papers — I

20 NOVEMBER

PROCEEDINGS OF THE XIV MEETING OF THE INTERNATIONAL STUDY GROUP FOR STEROID HORMONES

Plenary Lectures

Robert B. Dickson, Erik W. Thompson and Marc E. Lippman — 305 — Regulation of proliferation, invasion and growth factor synthesis in breast cancer by steroids

W. R. Miller and J. S. O'Neill — 317 — The significance of steroid metabolism in human cancer

Steroid Inhibitors

A. M. H. Brodie, P. K. Banks, S. E. Inkster, M. Dowsett and R. C. Coombes — 327 — Aromatase inhibitors and hormone-dependent cancers

R. De Coster, W. Wouters, C. R. Bowden, H. Vanden Bossche, J. Bruynseels, R. W. Tuman, R. Van Ginckel, E. Snoeck, A. Van Peer and P. A. J. Janssen — 335 — New non-steroidal aromatase inhibitors: focus on R76713

J. R. Pasqualini, N. Giambiagi, C. Gelly and G. Chetrite — 343 — Antiestrogen action in mammary cancer and in fetal cells

F. Sciarra, V. Toscano, G. Concolino and F. Di Silverio — 349 — Antiandrogens: clinical applications

A. S. Bhatnagar, A. Häusler, K. Schieweck, L. J. Browne, R. Bowman and R. E. Steele — 363 — Novel aromatase inhibitors

E. Di Salle, D. Giudici, G. Ornati, G. Briatico, R. D'Alessio, V. Villa and P. Lombardi — 369 — 4-Aminoandrostenedione derivatives: a novel class of irreversible aromatase inhibitors. Comparison with FCE 24304 and 4-hydroxyandrostenedione

Elizabeth Stoner — 375 — The clinical development of a 5α-reductase inhibitor, finasteride

Robert W. Brueggemeier, Pui-Kai Li, Hsiu-Ho Chen, Patrick P. Moh and Nancy E. Katlic — 379 — Biochemical and pharmacological development of steroidal inhibitors of aromatase

CNS Effects of Steroids

E. R. de Kloet, J. M. H. M. Reul and W. Sutanto — 387 — Corticosteroids and the brain

Etienne-Emile Baulieu and Paul Robel — 395 — Neurosteroids: a new brain function?

F. R. Patacchioli, P. Casolini, S. Puglisi-Allegra, A. G. Sadile and L. Angelucci 405 Hippocampal glucocorticoid receptor and behavior: a correlative study in rats and mice

Gaetano Frajese, Renato Lazzari, Armando Magnani, Costanzo Moretti, Vincenzo Sforza and Dina Nerozzi 411 Neurotransmitter, opiodergic system, steroid–hormone interaction and involvement in the replacement therapy of sexual disorders

Steroids and Aging

J. M. Kaufman, J. P. Deslypere, M. Giri and A. Vermeulen 421 Neuroendocrine regulation of pulsatile luteinizing hormone secretion in elderly men

A. M. Kaye, Y. Weisman, A. Harell and D. Sömjen 431 Hormonal stimulation of bone cell proliferation

Bandana Chatterjee and Arun K. Roy 437 Changes in hepatic androgen sensitivity and gene expression during aging

Claus Christiansen 447 Hormonal prevention and treatment of osteoporosis—state of the art 1990

Carlo Gennari and Donato Agnusdei 451 Calcitonin, estrogens and the bone

G. Mazzuoli, S. Minisola, G. Bianchi, M. T. Pacitti, R. Rosso, E. Romagnoli, V. Carnevale, L. Scarnecchia, F. S. Celi, V. Ortore and L. Carenza 457 The effects of oophorectomy on skeletal metabolism

L. P. C. Schot and A. H. W. M. Schuurs 461 Pathophysiology of bone loss in castrated animals

Forthcoming Papers 1

30 NOVEMBER

General Review

W. R. Miller 467 Endocrine treatment for breast cancers: biological rationale and current progress

Yuko Ohara-Nemoto, Per-Erik Strömstedt, Karin Dahlman-Wright, Takayuki Nemoto, Jan-Åke Gustafsson and Jan Carlstedt-Duke 481 The steroid-binding properties of recombinant glucocorticoid receptor: a putative role for heat shock protein hsp90

D. Sömjen, A. Harell, N. Jaccard, Y. Weisman and A. M. Kaye 491 Reciprocal modulation by sex steroid and calciotrophic hormones of skeletal cell proliferation

Ronald S. Snart 501 Characteristics of the calf uterine androgen receptor

T. Padayachi, R. J. Pegoraro, L. Rom and S. M. Joubert 509 Enzyme immunoassay of oestrogen and progesterone receptors in uterine and intrauterine tissue during human pregnancy and labour

Joanne R. Hayward, Arnold I. Coffer and Roger J. B. King 513 Immunoaffinity purification and characterisation of p29—an estrogen receptor related protein

P. D. Gupta, S. B. Relia, S. Bapu Rao and A. G. Reddy 521 Keratinization of rat vaginal epithelium—V. Modulation of intracellular calcium by estradiol

Susan J. Quirk, Jacquelyne A. Slattery and John W. Funder 529 Epithelial and adipose cells isolated from mammary glands of pregnant and lactating rats differ in 11β-hydroxysteroid dehydrogenase activity

Jean S. Campbell and Harry J. Karavolas 535 Characterization of the purified pituitary cytosolic NADPH:5α-dihydroprogesterone 3α-hydroxysteroid oxidoreductase

Salah E. Abdelgadir, Peter B. Connolly and John A. Resko 545 Androgen binding in peripheral tissues of fetal rhesus macaques: effects of androgen metabolism in liver

Giovanni De Pergola, Xuefan Xu, Shumin Yang, Riccardo Giorgino and Per Bjorntorp 553 Up-regulation of androgen receptor binding in male rat fat pad adipose precursor cells exposed to testosterone: study in a whole cell assay system

T. Suzuki, I. Horibe, N. Uchida, K. Ezumi, K. Uchida, K. Takeda, A. Tanaka, Y. Nishizawa and K. Matsumoto	559	Effects of antiandrogens on growth of androgen-dependent mouse mammary tumor (Shionogi carcinoma 115) *in vivo* and *in vitro*
Tetsuya Morikawa and Bun-ichi Tamaoki	569	Purification and characterization of 3α-hydroxysteroid dehydrogenase from chicken hepatic cytosol
Martin Brandt, Anthony T. Greway, Dennis A. Holt, Brian W. Metcalf and Mark A. Levy	575	Studies on the mechanism of steroid 5α-reductase inhibition by 3-carboxy A-ring aryl steroids
Adela Cuéllar, Vicente Díaz-Sánchez and Jorge Ramírez	581	Cholesterol side-chain cleavage and 11β-hydroxylation are inhibited by gossypol in adrenal cortex mitochondria
Narender Kumar, Ashok K. Didolkar, Anna Ladd, Rosemarie Thau, Carl Monder, C. Wayne Bardin and Kalyan Sundaram	587	Radioimmunoassay of 7α-methyl-19-nortestosterone and investigation of its pharmacokinetics in animals
Joseph Montalto, John W. Funder, Arthur B. W. Yong, Christopher B. Whorwood and John F. Connelly	593	Serum levels of 5-androstene-3β,17β-diol sulphate, 5α-androstane-3α,17β-diol sulphate and glucuronide, in late onset 21-hydroxylase deficiency
Y. Takeda, S. Lewicka, S. Koch, K. Bige, P. Vecsei, S. Abdelhamid, M. Cojocaru and M. Harnik	599	Synthesis of 19-nor-aldosterone, 18-hydroxy-19-nor-corticosterone and 18,19-dihydroxycorticosterone in the human aldosterone-producing adenoma
M. Laine and A. Ojanotko-Harri	605	Progesterone metabolism by major salivary glands of rat—II. Parotid gland
L. C. Lai and V. H. T. James	613	*In vitro* metabolism of testosterone by breast microcysts
Short Communication		
Paul S. Denker, David L. Vesely and Celso E. Gómez-Sánchez	617	Effect of pro-atrial natriuretic peptides 1–30, 31–67 and 99–126 on angiotensin II-stimulated aldosterone production in calf adrenal cells
Book Reviews	621	
Forthcoming Papers	I	

10 DECEMBER

A. K. Mukhopadhyay, N. Temmen, K. P. Willey and F. A. Leidenberger	623	Histones inhibit human chorionic gonadotrophin-stimulated but not atrial peptide-stimulated testosterone production and cyclic nucleotide formation by isolated mouse Leydig cells
Maryanne C. McClellan, Susannah Rankin, Neal B. West and Robert M. Brenner	631	Estrogen receptors, progestin receptors and DNA synthesis in the macaque endometrium during the luteal–follicular transition
S. Marsigliante, J. R. Puddefoot, S. Barker, J. Gledhill and G. P. Vinson	643	Discrepancies between antibody (EIA) and saturation analysis of oestrogen receptor content in breast tumour samples
Beverly S. Chilton and Linda S. Geis	649	Steroid receptors in the developing and the adult rabbit endocervix and in endocervical epithelial cells isolated by flow cytometry
Chhanda Gupta, Veronica Wharton and Demetrius Ellis	661	Anti-masculinizing action of estradiol and cyproterone acetate: regulation of a protein fraction with phospholipase-A_2 stimulatory and masculinizing activities
Azra Khanum and Maria L. Dufau	669	A cAMP independent inhibitory action of high doses of forskolin in rat Leydig cells
Eisuke P. Murono and Amie L. Washburn	675	Evidence that Leydig precursors localize in immature band two cells isolated on Percoll gradients

Emanuel Levin, Silvia Tomchinsky and Silvia López	681	Displacement by tamoxifen of the estradiol–estrogen receptor binding: a functional assay for breast cancer studies
Ida E. Tóth, K. Sz. Szalay, D. Szabó and J. Pill	687	Effect of a cholesterol synthesis inhibitor (BM 15.766) in the presence and absence of HDL on corticosteroidogenesis of isolated zona glomerulosa and fasciculata cells
M. Bhattacharjee and E. Ali	693	Binding of estradiol-peroxidase conjugate to estrogen receptor
Jaime Steinsapir and Thomas G. Muldoon	697	Specific binding of androgen and androgen–receptor complex by microsomes from rat ventral prostate
Sandra M. Glutek and Ron Hobkirk	707	Estrogen sulfatase and steroid sulfatase activities in intrauterine tissues of the pregnant guinea pig
Yasuro Sugimoto, Masamitsu Yoshida and Bun-ichi Tamaoki	717	Purification of 5β-reductase from hepatic cytosol fraction of chicken
Lisa Biegel and Stephen Safe	725	Effects of 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD) on cell growth and the secretion of the estrogen-induced 34-, 52- and 160-kDa proteins in human breast cancer cells
Simon E. J. Edmunds, Andrew P. Stubbs, Antonio A. Santos and Mark L. Wilkinson	733	Estrogen and androgen regulation of sex hormone binding globulin secretion by a human liver cell line
Shigeki Taga, Nobutaka Yoshida and Kaoru Sekiba	741	Distribution and cyclic change of aromatase cytochrome *P*-450 activity in human uteri
Forthcoming Papers	I	
Corrigenda	III	

20 DECEMBER

Proceedings of the 2nd International EORTC Symposium on HORMONAL MANIPULATION OF CANCER: PEPTIDES, GROWTH FACTORS AND NEW (ANTI-)STEROIDAL AGENTS

Preface	vii	
I. Steroid Receptors and New (Anti-)Steroidal Agents		
Stephen Green	747	Modulation of oestrogen receptor activity by oestrogens and anti-oestrogens
Philippa D. Darbre and Roger J. Daly	753	Transition of human breast cancer cells from an oestrogen responsive to unresponsive state
David F. C. Gibson, Marco M. Gottardis and V. Craig Jordan	765	Sensitivity and insensitivity of breast cancer to tamoxifen
A. E. Wakeling	771	Therapeutic potential of pure antioestrogens in the treatment of breast cancer
Gilles Freiss, Christine Prebois, Henri Rochefort and Françoise Vignon	777	Anti-steroidal and anti-growth factor activities of anti-estrogens
M. R. Schneider, H. Michna, Y. Nishino and M. F. El Etreby	783	Antitumor activity and mechanism of action of different antiprogestins in experimental breast cancer models
G. H. Bakker, B. Setyono-Han, H. Portengen, F. H. De Jong, J. A. Foekens and J. G. M. Klijn	789	Treatment of breast cancer with different antiprogestins: preclinical and clinical studies
II. Oncogenes and Growth Factors		
Robert B. Dickson	795	Stimulatory and inhibitory growth factors and breast cancer
C. Kent Osborne, David R. Clemmons and Carlos L. Arteaga	805	Regulation of breast cancer growth by insulin-like growth factors

Stewart Nicholson, Christopher Wright, J. Richard C. Sainsbury, Pauline Halcrow, Peter Kelly, Brian Angus, John R. Farndon and Adrian L. Harris	811	Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: neu and tamoxifen failure
J. A. Foekens, W. L. J. van Putten, H. Portengen, C. J. Rodenburg, J.-C. Reubi, P. M. J. J. Berns, S. C. Henzen-Logmans, M. E. L. van der Burg, J. Alexieva-Figusch and J. G. M. Klijn	815	Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancer
J. P. Peyrat, J. Bonneterre, P. H. Vennin, H. Jammes, R. Beuscart, B. Hecquet, J. Djiane, J. Lefebvre and A. Demaille	823	Insulin-like growth factor 1 receptors (IGF1-R) and IGF1 in human breast tumors
A. H. Bootsma, A. de Klein, J. C. Reubi, E. C. Zwarthoff and S. W. J. Lamberts	829	Genetic changes in somatostatin receptor positive breast tumors
R. C. Coombes, P. Barrett-Lee and Y. Luqmani	833	Growth factor expression in breast tissue
J. Trapman, C. Ris-Stalpers, J. A. G. M. van der Korput, G. G. J. M. Kuiper, P. W. Faber, J. C. Romijn, E. Mulder and A. O. Brinkmann	837	The androgen receptor: functional structure and expression in transplanted human prostate tumors and prostate tumor cell lines
Paul S. Rennie, Nicholas Bruchovsky and Andrew J. Coldman	843	Loss of androgen dependence is associated with an increase in tumorigenic stem cells and resistance to cell-death genes
A. L. G. Schuurmans, J. Bolt, J. Veldscholte and E. Mulder	849	Stimulatory effects of antiandrogens on LNCaP human prostate tumor cell growth, EGF-receptor level and acid phosphatase secretion
Thomas Bauknecht, Gerlinde Birmelin and Friedrich Kommoss	855	Clinical significance of oncogenes and growth factors in ovarian carcinomas
F. H. De Jong, A. J. Grootenhuis, J. Steenbergen, F. J. van Sluijs, J. A. Foekens, F. J. W. ten Kate, J. W. Oosterhuis, S. W. J. Lamberts and J. G. M. Klijn	863	Inhibin immunoreactivity in gonadal and non-gonadal tumors
A. R. M. M. Hermus and C. G. J. Sweep	867	Cytokines and the hypothalamic–pituitary–adrenal axis
H. A. P. Pols, J. C. Birkenhäger, J. A. Foekens and J. P. T. M. van Leeuwen	873	Vitamin D: a modulator of cell proliferation and differentiation
Klaus Havemann, Martin Rotsch, Hans-Josef Schöneberger, Cebrail Erbil, Cordula Hennig and Gabriele Jaques	877	Growth regulation by insulin-like growth factors in lung cancer
Simon P. Robinson, William C. Rose and AnnaMaria Casazza	883	*In vivo* evaluation of epidermal growth factor and transforming growth factor β_1 in mouse tumor models
John Mendelsohn	889	Anti-epidermal growth factor receptor monoclonal antibodies as potential anti-cancer agents
Renato V. La Rocca, Cy A. Stein, Romano Danesi and Charles E. Myers	893	Suramin, a novel antitumor compound

III. Hormonal Treatment of Prostate Cancer (in Honour of Professor H. J. de Voogt)

A. Qayum, W. J. Gullick, K. Mellon, T. Krausz, D. Neal, K. Sikora and J. Waxman	899	The partial purification and characterization of GnRH-like activity from prostatic biopsy specimens and prostatic cancer cell lines

W. M. van Weerden, G. J. van Steenbrugge, A. van Kreuningen, E. P. C. M. Moerings, F. H. De Jong and F. H. Schröder	903	Effects of low testosterone levels and of adrenal androgens on growth of prostate tumor models in nude mice
M. Namer, J. Toubol, A. Katy, J. E. Couette, J. Douchez, P. Kerbrat and J. P. Droz	909	A randomized double-blind study evaluating Anandron® associated with orchiectomy in stage D prostate cancer
Finn Rasmussen	917	Long-term treatment with antiandrogens
C. Mahler and L. Denis	921	Clinical profile of a new non-steroidal antiandrogen
J. Sandow, K. Stoeckemann and G. Jerabek-Sandow	925	Pharmacokinetics and endocrine effects of slow release formulations of LHRH analogues
G. A. Dijkman, P. Fernandez del Moral, J. W. M. H. Plasman, J. J. M. Kums, K. P. J. Delaere, F. M. J. Dubruyne, F. J. Hutchinson and B. J. A. Furr	933	A new extra long acting depot preparation of the LHRH analogue Zoladex®. First endocrinological and pharmacokinetic data in patients with advanced prostate cancer
Ursula-F. Habenicht, Martin R. Schneider and M. Fathy El Etreby	937	Effect of the new potent LHRH antagonist antide
F. Labrie, A. Dupont, L. Cusan, J. Gomez, J. Emond and G. Monfette	943	Combination therapy with flutamide and medical (LHRH agonist) or surgical castration in advanced prostate cancer: 7-year clinical experience
L. Denis, M. Robinson, C. Mahler, Ph. Smith, F. Keuppens, J. L. Carneiro De Moura, A. Bono, D. Newling, R. Sylvester, M. De Pauw, K. Vermeylen, P. Ongena and Members of the EORTC-GU Group	951	Orchidectomy versus Zoladex® plus Eulexin® in patients with metastatic prostate cancer (EORTC 30853)
E. David Crawford and Judith A. Allen	961	Treatment of newly diagnosed stage D2 prostate cancer with leuprolide and flutamide or leuprolide alone, phase III, intergroup study 0036
H. J. de Voogt, J. G. M. Klijn, U. Studer, F. Schröder, R. Sylvester, M. De Pauw and Members of the EORTC-GU Group	965	Orchidectomy versus Buserelin in combination with cyproterone acetate, for 2 weeks or continuously, in the treatment of metastatic prostatic cancer. Preliminary results of EORTC-trial 30843
D. W. W. Newling, S. Fossa, U. Tunn, K. H. Kurth, M. De Pauw, R. Sylvester and Members of the EORTC-GU Group	971	Comparison of the effects of high dose Estramustine phosphate and Mitomycin C on the time to progression and length of survival of patients with progressive, advanced endocrine-independent prostatic cancer: an interim analysis of EORTC-GU Group Study No. 30865
IV. Peptide Hormones and Cancer		
J. Bonneterre, J. P. Peyrat, R. Beuscart and A. Demaille	977	Biological and clinical aspects of prolactin receptors (PRL-R) in human breast cancer
L. Dogliotti, A. Berruti, T. Buniva, M. Torta, A. Bottini, M. Tampellini, M. Terzolo, R. Faggiuolo and A. Angeli	983	Melatonin and human cancer
R. I. Nicholson, K. J. Walker, R. A. McClelland, A. Dixon, J. F. R. Robertson and R. W. Blamey	989	Zoladex® plus tamoxifen versus Zoladex® alone in pre- and peri-menopausal metastatic breast cancer
P. G. Satyaswaroop and R. Mortel	997	Hormonal treatment of endometrial carcinoma: an overview and new development in biology
Günter Emons, Gurcharan S. Pahwa, Olaf Ortmann, Rudolf Knuppen, Friedhelm Oberheuser and Klaus-Dieter Schulz	1003	LHRH-receptors and LHRH-agonist treatment in ovarian cancer: an overview
C. N. d'Arville and P. J. Johnson	1007	Growth factors, endocrine aspects and hormonal treatment in hepatocellular carcinoma—an overview

V. Enzyme Inhibitors

P. F. Bruning, J. M. G. Bonfrèr, J. Wildiers, J. Jassem, L. V. A. M. Beex, J. Schornagel and W. J. Nooijen on behalf of the EORTC Breast Cancer Cooperative 1013 Second line endocrine treatment of postmenopausal advanced breast cancer. Preliminary endocrine results of a 5-arm randomized Phase II trial of medium vs low dose aminoglutethimide, with or without hydrocortisone vs hydrocortisone alone (EORTC 10861)

A. S. Bhatnagar, A. Häusler, K. Schieweck, M. Lang and R. Bowman 1021 Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor

Richard J. Santen 1029 Recent progress in development of aromatase inhibitors

M. Dowsett 1037 Clinical development of aromatase inhibitors for the treatment of breast and prostate cancer

A. M. H. Brodie, P. K. Banks, S. E. Inkster, C. Son and R. D. Koos 1043 Aromatase and other inhibitors in breast and prostatic cancer

Walter Wouters, Roland De Coster, Jacky van Dun, Marita D. W. G. Krekels, Ann Dillen, Alfons Raeymaekers, Eddy Freyne, Jozef Van Gelder, Gérard Sanz, Marc Venet and Marcel Janssen 1049 Comparative effects of the aromatase inhibitor R76713 and of its enantiomers R83839 and R83842 on steroid biosynthesis *in vitro* and *in vivo*

W. R. Miller, T. J. Anderson and W. J. L. Jack 1055 Relationship between tumour aromatase activity, tumour characteristics and response to therapy

VI. Somatostatin Analogs and Cholecystokinin Inhibitors

A. V. Schally, G. Srkalovic, B. Szende, T. W. Redding, T. Janaky, A. Juhasz, E. Korkut, R.-Z. Cai, K. Szepeshazi, S. Radulovic, L. Bokser, K. Groot, P. Serfozo and A. M. Comaru-Schally 1061 Antitumor effects of analogs of LH-RH and somatostatin: experimental and clinical studies

C. B. H. W. Lamers, J. B. M. J. Jansen and R. A. Woutersen 1069 Cholecystokinin and gastrointestinal cancer

J.-C. Reubi, E. Krenning, S. W. J. Lamberts and L. Kvols 1073 Somatostatin receptors in malignant tissues

S. W. J. Lamberts, W. H. Bakker, J.-C. Reubi and E. P. Krenning 1079 Somatostatin receptor imaging. *In vivo* localization of tumors with a radiolabeled somatostatin analog

Andrea Manni, Alice E. Boucher, Laurence M. Demers, Harold A. Harvey, Allan Lipton, Mary A. Simmonds and Mary Bartholomew 1083 Somatostatin analogues in the treatment of breast and prostate cancer

J. G. M. Klijn, B. Setyono-Han, G. H. Bakker, M. E. L. van der Burg, M. Bontenbal, H. A. Peters, A. M. Sieuwerts, P. M. J. J. Berns and J. A. Foekens 1089 Growth factor-receptor pathway interfering treatment by somatostatin analogs and suramin: preclinical and clinical studies

VII. Hormonal Recruitment and Chemotherapy

M. Bontenbal, A. M. Sieuwerts, H. A. Peters, P. Sonneveld, J. A. Foekens and J. G. M. Klijn 1097 Manipulation of cell cycle kinetics: influence on the cytotoxicity of doxorubicin in human breast cancer cells

P. F. Conte, G. Gardin, P. Pronzato, L. Miglietta, R. Rosso, D. Amadori, P. Gentilini, C. Monzeglio, P. Gallotti, R. Demicheli, F. Brema, P. Sismondi, P. Miccoli, C. Lanfranco, F. Minuto, A. Barreca and P. Del Monte 1103 *In vivo* manipulation of human breast cancer growth by estrogens and growth hormone: kinetic and clinical results

R. Paridaens, J. C. Heuson, J. P. Julien, C. Veyret, J. van Zijl, J. G. M. Klijn, R. J. Sylvester, F. Mignolet and the EORTC Breast Cancer Cooperative Group 1109 Assessment of estrogenic recruitment before chemotherapy in advanced breast cancer: preliminary results of a double-blind randomized study of the EORTC Breast Cancer Cooperative Group

R. J. Santen, A. Manni, H. F. English and D. Heitjan 1115 Androgen-primed chemotherapy—experimental confirmation of efficacy

Forthcoming Papers I

Announcement II